Novo Nordisk A/S - NVO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $682.43
  • Forecasted Upside: 584.96 %
  • Number of Analysts: 20
  • Breakdown:
  • 2 Sell Ratings
  • 6 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$99.63
▼ -0.76 (-0.76%)

This chart shows the closing price for NVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novo Nordisk A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVO

Analyst Price Target is $682.43
▲ +584.96% Upside Potential
This price target is based on 20 analysts offering 12 month price targets for Novo Nordisk A/S in the last 3 months. The average price target is $682.43, with a high forecast of $900.00 and a low forecast of $130.00. The average price target represents a 584.96% upside from the last price of $99.63.

This chart shows the closing price for NVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 20 polled investment analysts is to buy stock in Novo Nordisk A/S. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 2 sell ratings
4/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 2 sell ratings
7/7/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 2 sell ratings
10/5/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 1 sell ratings
1/3/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 2 sell ratings
4/3/2022
  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 2 sell ratings
7/2/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 2 sell ratings
8/31/2022
  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 2 sell ratings
9/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/29/2022Oddo BhfUpgradeNeutral ➝ OutperformLow
7/15/2022Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
6/28/2022UBS GroupDowngradeNeutral ➝ SellLow
6/27/2022Exane BNP ParibasUpgradeUnderperform ➝ Neutral750.00Low
6/27/2022BNP ParibasUpgradeUnderperform ➝ Neutral$750.00Low
6/7/2022JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightLow
5/31/2022GuggenheimUpgradeNeutral ➝ BuyLow
5/12/2022BarclaysBoost TargetOverweight ➝ Overweight850.00 ➝ 875.00Low
5/5/2022Bryan, Garnier & CoUpgradeSell ➝ NeutralLow
5/4/2022Deutsche Bank AktiengesellschaftBoost Target850.00 ➝ 900.00Low
4/25/2022CowenUpgradeMarket Perform ➝ Outperform$130.00High
4/25/2022CowenUpgradeMarket Perform ➝ OutperformHigh
4/19/2022Berenberg BankBoost TargetHold ➝ Hold585.00 ➝ 780.00Low
4/14/2022BarclaysBoost Target750.00 ➝ 850.00Low
4/12/2022Morgan StanleyUpgradeUnderweight ➝ Equal WeightMedium
3/16/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyLow
3/2/2022CitigroupUpgradeNeutral ➝ BuyMedium
3/1/2022Berenberg BankBoost TargetHold ➝ Hold530.00 ➝ 585.00Low
2/28/2022Stifel NicolausInitiated CoverageBuyLow
2/3/2022DanskeUpgradeHold ➝ BuyMedium
1/25/2022Liberum CapitalDowngradeHold ➝ SellMedium
12/20/2021CitigroupDowngradeBuy ➝ NeutralMedium
12/20/2021JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralMedium
12/20/2021DanskeDowngradeBuy ➝ HoldMedium
12/17/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldMedium
11/11/2021UBS GroupReiterated RatingNeutralLow
11/4/2021BarclaysReiterated RatingOverweightMedium
11/4/2021Credit Suisse GroupReiterated RatingNeutralMedium
11/4/2021JPMorgan Chase & Co.Reiterated RatingOverweightMedium
11/3/2021Bryan, Garnier & CoDowngradeBuy ➝ Sell592.00High
11/2/2021Morgan StanleyReiterated RatingUnderweightLow
11/1/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
10/29/2021DNB MarketsDowngradeBuy ➝ HoldHigh
10/18/2021SEB EquitiesUpgradeHold ➝ BuyLow
9/3/2021Berenberg BankReiterated RatingHoldLow
8/23/2021Credit Suisse GroupReiterated RatingNeutralHigh
8/23/2021CitigroupReiterated RatingBuyLow
8/17/2021UBS GroupReiterated RatingNeutralLow
8/11/2021Morgan StanleyReiterated RatingUnderweightLow
8/6/2021JPMorgan Chase & Co.Reiterated RatingOverweightLow
8/5/2021BarclaysReiterated RatingOverweightHigh
8/5/2021Bank of AmericaUpgradeNeutral ➝ BuyHigh
8/5/2021DNB MarketsUpgradeHold ➝ BuyHigh
8/3/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyHigh
7/19/2021BarclaysReiterated RatingOverweightMedium
7/15/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyMedium
2/11/2021UBS GroupReiterated RatingNeutralLow
2/4/2021BarclaysReiterated RatingOverweightLow
1/20/2021Credit Suisse GroupDowngradeOutperform ➝ NeutralMedium
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuyLow
11/12/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
11/6/2020Morgan StanleyDowngradeEqual Weight ➝ UnderweightHigh
11/3/2020Societe GeneraleReiterated RatingSellLow
10/15/2020Morgan StanleyReiterated RatingEqual WeightLow
9/29/2020Berenberg BankInitiated CoverageHoldMedium
8/18/2020UBS GroupReiterated RatingNeutralLow
8/3/2020Morgan StanleyReiterated RatingEqual WeightLow
7/6/2020Bank of AmericaDowngradeBuy ➝ NeutralLow
5/18/2020Morgan StanleyReiterated RatingEqual WeightMedium
5/13/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
5/11/2020UBS GroupDowngradeBuy ➝ NeutralMedium
5/7/2020Societe GeneraleReiterated RatingSellLow
5/4/2020CowenInitiated CoverageMarket Perform$72.00Low
3/23/2020UBS GroupUpgradeNeutral ➝ BuyMedium
3/16/2020Bank of AmericaUpgradeNeutral ➝ BuyHigh
1/3/2020GuggenheimDowngradeBuy ➝ NeutralLow
11/27/2019BarclaysUpgradeEqual Weight ➝ OverweightMedium
11/22/2019Pareto SecuritiesDowngradeBuy ➝ HoldLow
11/18/2019UBS GroupDowngradeBuy ➝ NeutralLow
11/18/2019BarclaysUpgradeEqual Weight ➝ OverweightHigh
9/17/2019CitigroupUpgradeNeutral ➝ BuyLow
9/13/2019Bank of AmericaBoost TargetNeutral$355.00 ➝ $400.00Low
8/30/2019Jefferies Financial GroupDowngradeHold ➝ UnderperformLow
8/5/2019Pareto SecuritiesUpgradeHold ➝ BuyLow
6/20/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$52.42Medium
6/19/2019UBS GroupReiterated RatingBuy$355.00Medium
6/11/2019BarclaysUpgradeUnderweight ➝ Equal Weight$51.85Low
4/30/2019Pareto SecuritiesDowngradeBuy ➝ HoldLow
4/29/2019Credit Suisse GroupUpgradeNeutral ➝ OutperformLow
2/5/2019BarclaysReiterated RatingSellLow
2/4/2019HandelsbankenDowngradeBuy ➝ Accumulate$48.61Low
2/1/2019Morgan StanleyInitiated CoverageEqual WeightLow
1/29/2019BNP ParibasInitiated CoverageOutperformLow
12/14/2018Morgan StanleyInitiated CoverageEqual WeightLow
12/11/2018Jefferies Financial GroupReiterated RatingHold ➝ HoldMedium
12/10/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyMedium
12/2/2018UBS GroupReiterated RatingBuyMedium
11/29/2018Kepler Capital MarketsReiterated RatingHoldLow
11/26/2018HSBCReiterated RatingSellLow
11/26/2018UBS GroupReiterated RatingBuyLow
11/26/2018Pareto SecuritiesUpgradeHold ➝ BuyLow
11/19/2018JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightLow
11/6/2018HSBCReiterated RatingSellMedium
11/2/2018CfraReiterated RatingHoldLow
10/18/2018Kepler Capital MarketsReiterated RatingHoldLow
10/8/2018GuggenheimInitiated CoverageBuy ➝ BuyMedium
10/8/2018Bank of AmericaDowngradeBuy ➝ NeutralLow
10/5/2018Pareto SecuritiesDowngradeBuy ➝ HoldLow
10/4/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
7/2/2018Sanford C. BernsteinUpgradeMarket Perform ➝ OutperformLow
1/8/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
12/29/2017JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralLow
12/6/2017Bank of AmericaUpgradeNeutral ➝ BuyMedium
12/1/2017Morgan StanleyUpgradeEqual Weight ➝ OverweightMedium
(Data available from 9/30/2017 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 16 positive mentions
  • 8 negative mentions
  • 1 very negative mentions
3/4/2022
  • 8 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/3/2022
  • 7 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/3/2022
  • 10 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/2/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/2/2022
  • 8 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
8/1/2022
  • 7 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
8/31/2022
  • 9 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
9/30/2022

Current Sentiment

  • 9 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Novo Nordisk A/S logo
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Read More

Today's Range

Now: $99.63
Low: $99.57
High: $100.72

50 Day Range

MA: $105.64
Low: $95.28
High: $116.93

52 Week Range

Now: $99.63
Low: $91.51
High: $122.16

Volume

1,094,578 shs

Average Volume

1,561,359 shs

Market Capitalization

$225.46 billion

P/E Ratio

29.74

Dividend Yield

0.81%

Beta

0.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Novo Nordisk A/S?

The following Wall Street analysts have issued stock ratings on Novo Nordisk A/S in the last year: Barclays PLC, Berenberg Bank, BNP Paribas, Bryan, Garnier & Co, Citigroup Inc., Cowen Inc, Cowen Inc., Credit Suisse Group AG, Danske, Deutsche Bank Aktiengesellschaft, DNB Markets, Exane BNP Paribas, Guggenheim, JPMorgan Chase & Co., Liberum Capital, Morgan Stanley, Oddo Bhf, SEB Equities, Stifel Nicolaus, StockNews.com, and UBS Group AG.
View the latest analyst ratings for NVO.

What is the current price target for Novo Nordisk A/S?

7 Wall Street analysts have set twelve-month price targets for Novo Nordisk A/S in the last year. Their average twelve-month price target is $682.43, suggesting a possible upside of 585.0%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting NVO will reach $900.00 in the next twelve months. Cowen Inc. has the lowest price target set, forecasting a price of $130.00 for Novo Nordisk A/S in the next year.
View the latest price targets for NVO.

What is the current consensus analyst rating for Novo Nordisk A/S?

Novo Nordisk A/S currently has 2 sell ratings, 6 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NVO will outperform the market and that investors should add to their positions of Novo Nordisk A/S.
View the latest ratings for NVO.

What other companies compete with Novo Nordisk A/S?

Other companies that are similar to Novo Nordisk A/S include Merck & Co., Inc., Pfizer, AbbVie, Abbott Laboratories and AstraZeneca. Learn More about companies similar to Novo Nordisk A/S.

How do I contact Novo Nordisk A/S's investor relations team?

Novo Nordisk A/S's physical mailing address is Novo Alle, Bagsvaerd G7, 2880. The company's listed phone number is (454) 444-8888 and its investor relations email address is [email protected] The official website for Novo Nordisk A/S is www.novonordisk.com. Learn More about contacing Novo Nordisk A/S investor relations.